Espen Basmo相关文献与解析，生知库 | 链接生命科学的每一步

Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials

接种长肽癌症疫苗 UV1 后持久且动态的 hTERT 免疫反应：三项 I 期临床试验的长期随访

doi:10.1136/jitc-2021-004345

Espen Basmo Ellingsen, Elin Aamdal, Tormod Guren, Wolfgang Lilleby, Paal F Brunsvig, Sara M Mangsbo, Steinar Aamdal, Eivind Hovig, Nadia Mensali, Gustav Gaudernack, Else Marit Inderberg0

免疫

发表日期：2022

文献求助收藏

Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination

伊匹单抗和 hTERT 疫苗联合治疗后 T 细胞受体库和黑色素瘤肿瘤微环境的表征

期刊:Journal of Translational Medicine

影响因子:6.1

doi:10.1186/s12967-022-03624-z

Espen Basmo Ellingsen, Gergana Bounova, Iliana Kerzeli, Irantzu Anzar, Donjete Simnica, Elin Aamdal, Tormod Guren, Trevor Clancy, Artur Mezheyeuski, Else Marit Inderberg, Sara M Mangsbo, Mascha Binder, Eivind Hovig, Gustav Gaudernack4

Personalized HLA typing leads to the discovery of novel HLA alleles and tumor-specific HLA variants

个性化HLA分型有助于发现新的HLA等位基因和肿瘤特异性HLA变异体。

期刊:HLA

影响因子:4.1

doi:10.1111/tan.14562

Anzar, Irantzu; Sverchkova, Angelina; Samarakoon, Pubudu; Ellingsen, Espen Basmo; Gaudernack, Gustav; Stratford, Richard; Clancy, Trevor

NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma

NIPU：一项随机、开放标签的 II 期研究，评估纳武利尤单抗和伊匹木单抗联合 UV1 疫苗作为恶性间皮瘤患者二线治疗方案的疗效。

期刊:Journal of Translational Medicine

影响因子:7.5

doi:10.1186/s12967-021-02905-3

Haakensen, Vilde Drageset; Nowak, Anna K; Ellingsen, Espen Basmo; Farooqi, Saima Jamil; Bjaanæs, Maria Moksnes; Horndalsveen, Henrik; Mcculloch, Tine; Grundberg, Oscar; Cedres, Susana M; Helland, Åslaug

发表日期：2021

文献求助收藏

Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential

端粒酶作为癌症治疗疫苗的靶点及其优化临床应用潜力的考量

期刊:Frontiers in Immunology

影响因子:5.9

doi:10.3389/fimmu.2021.682492

Ellingsen, Espen Basmo; Mangsbo, Sara M; Hovig, Eivind; Gaudernack, Gustav

Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial

将通用端粒酶癌症疫苗与伊匹单抗联合用于转移性黑色素瘤患者 - I/IIa 期临床试验的五年随访

期刊:Frontiers in Immunology

影响因子:5.7

doi:10.3389/fimmu.2021.663865

Elin Aamdal, Else Marit Inderberg, Espen Basmo Ellingsen, Wenche Rasch, Paal Fredrik Brunsvig, Steinar Aamdal, Karen-Marie Heintz, Daniel Vodák, Sigve Nakken, Eivind Hovig, Marta Nyakas, Tormod Kyrre Guren, Gustav Gaudernack

Therapeutic cancer vaccination against telomerase: clinical developments in melanoma

针对端粒酶的治疗性癌症疫苗：黑色素瘤的临床进展

Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials

接种长肽癌症疫苗 UV1 后持久且动态的 hTERT 免疫反应：三项 I 期临床试验的长期随访

Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination

伊匹单抗和 hTERT 疫苗联合治疗后 T 细胞受体库和黑色素瘤肿瘤微环境的表征

Personalized HLA typing leads to the discovery of novel HLA alleles and tumor-specific HLA variants

个性化HLA分型有助于发现新的HLA等位基因和肿瘤特异性HLA变异体。

NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma

NIPU：一项随机、开放标签的 II 期研究，评估纳武利尤单抗和伊匹木单抗联合 UV1 疫苗作为恶性间皮瘤患者二线治疗方案的疗效。

Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential

端粒酶作为癌症治疗疫苗的靶点及其优化临床应用潜力的考量

Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial

将通用端粒酶癌症疫苗与伊匹单抗联合用于转移性黑色素瘤患者 - I/IIa 期临床试验的五年随访